- Home
- CAL vs CRVS Comparison
CAL vs CRVS Comparison
Compare CAL & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAL
- CRVS
- Stock Information
- Founded
- CAL 1878
- CRVS 2014
- Country
- CAL United States
- CRVS United States
- Employees
- CAL N/A
- CRVS N/A
- Industry
- CAL Shoe Manufacturing
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- CAL Consumer Discretionary
- CRVS Health Care
- Exchange
- CAL Nasdaq
- CRVS Nasdaq
- Market Cap
- CAL 446.5M
- CRVS 459.0M
- IPO Year
- CAL N/A
- CRVS 2016
- Fundamental
- Price
- CAL $15.45
- CRVS $6.06
- Analyst Decision
- CAL Hold
- CRVS Strong Buy
- Analyst Count
- CAL 1
- CRVS 4
- Target Price
- CAL $14.00
- CRVS $15.00
- AVG Volume (30 Days)
- CAL 844.1K
- CRVS 582.7K
- Earning Date
- CAL 09-04-2025
- CRVS 11-11-2025
- Dividend Yield
- CAL 1.80%
- CRVS N/A
- EPS Growth
- CAL N/A
- CRVS N/A
- EPS
- CAL 1.76
- CRVS N/A
- Revenue
- CAL $2,652,908,000.00
- CRVS N/A
- Revenue This Year
- CAL N/A
- CRVS N/A
- Revenue Next Year
- CAL $2.11
- CRVS N/A
- P/E Ratio
- CAL $8.84
- CRVS N/A
- Revenue Growth
- CAL N/A
- CRVS N/A
- 52 Week Low
- CAL $12.09
- CRVS $2.54
- 52 Week High
- CAL $37.70
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- CAL 54.80
- CRVS 64.32
- Support Level
- CAL $15.10
- CRVS $5.90
- Resistance Level
- CAL $16.14
- CRVS $6.30
- Average True Range (ATR)
- CAL 0.67
- CRVS 0.31
- MACD
- CAL 0.03
- CRVS 0.01
- Stochastic Oscillator
- CAL 79.40
- CRVS 75.98
About CAL Caleres Inc.
Caleres Inc is a footwear company that operates retail shoe stores and e-commerce websites, and designs, develops, sources, manufactures, and distributes footwear for people of all ages. The Company's business operations are organized into two reportable segments - famous Footwear and Brand Portfolio. The famous Footwear segment is comprised of its famous Footwear retail stores, famousfootwear.com, and famousfootwear.ca. The famous Footwear segment operated around 846 stores at the end of 2024. The Brand Portfolio segment offers retailers and consumers a cultivated portfolio of known brands. Geographically, the company generates the majority of its revenue from Domestic operations.
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).